NanoSphere Health Sciences (
CSE: NSHS,
OTCQB: NSHSF,
Forum) is already familiar to Stockhouse’s cannabis investors. The Company was first covered in a full-length Stockhouse feature article from
February 12, 2019. That article alerted Stockhouse investors to “nanoencapsulation”, the research approach from which NanoSphere draws its name and has received two U.S. patents.
In essence, NanoSpheres nanoencapsulation creates nanosized lipid molecular structures that efficiently deliver bioactive and therapeutic compounds direct to target receptors with greater bioavialbility. This allows for applications direct through the skin, mouth’s mucosa, and through nose directly to the brain, avoiding the digestive tract and “first pass” liver metabolism. A pharmacokinetic clinical study conducted by NanoSphere demonstrated the superiority of the NanoSphere Delvery System versus standard delivery methods already on the market.
Given the efficacy of this smart nanoparticle delivery biotechnology, the Company’s R&D team took on a new challenge. If the NanoSphere Delivery System can effectively protect and significantly improve the delivery of cannabinoid molecules, could it also be used to improve the therapeutic potential and decrease the adverse effects of popular medications?
This is an important issue for medical practitioners and their patients. Many efficacious drugs produce many undesirable side effects – including gastrointestinal, liver and kidney problems.
On April 24, 2019; NanoSphere announced it had received a “Notice of Allowance” from the Canadian Intellectual Property Office (CIPO) with respect to
extending the scope of the Company’s master patent, covering the NanoSphere Delivery System™.
Specifically, this patent breakthrough covers “The Method of Treating Inflammatory Disorders and Global Inflammation with Phospholipid Nanoparticle Encapsulation of NSAIDs.” NSAID refers to Non-Steroidal Anti-Inflammatory Drugs. Most readers will be more familiar with this class of drugs as being
over-the-counter medications for pain and inflammation relief, including aspirin, ibuprofen, and naproxen.
Ironically, these drugs taken to produce anti-inflammatory relief tend to cause gastrointestinal inflammation and irritation as side effects. For consumers and drug companies alike, a patent to minimize or eliminate this undesirable side effect is big news.
This Notice of Allowance will also be seen by many investors as further validation of NanoSphere’s nanoencapsulation technology. The Company has been granted a broader extension of this patent by CIPO
because it works.
Richard Clark Kaufman, Chief Science Officer for NanoSphere offered additional details here.
“Nanoencapsulating NSAIDs in a stable nanoparticle structure
allows for a more rapid onset of symptom relief, longer lasting activity, greater therapeutic activity from a smaller dose and potential reduction of dangerous side effects. The NSAID class of drugs are very effective, but they can also create an increased risk of gastrointestinal bleeding or ulcers, heart attacks, kidney disease, and liver failure.” [emphasis mine]
Faster acting, greater efficacious effect for the medication contained, and the reduction of side effects. It’s easy to see a scramble by drug-makers to seek to license this technology for their own NSAID medications.
NanoSphere’s CEO, Robert Sutton framed this news in Big Picture terms.
“The granting of the patent for the NanoSphere Delivery System™ further secures our position as the leader in advanced nanoparticle delivery. Through our research and development,
we aim to be the de facto mode for NSAID delivery worldwide.” [emphasis mine]
For investors seeking to assess the global profit potential of this technology, the
market for anti-inflammatory therapeutics is expected to reach US$130.6 billion by 2026, expanding at a CAGR of 8.5%. Even a small piece of this very large pie can potentially provide enormous push for a Company with a current market cap of
just under $30 million.
Producing winning technology for the efficient delivery of cannabinoids was already a large prize for which NanoSphere sees itself as a leading contender. Now NanoSphere has raised the bar. As a potentially revolutionary solution for the delivery of NSAID’s, NanoSphere Health Sciences is establishing itself as a serious biopharma investment opportunity that extends well beyond the cannabis space.
www.nanospherehealth.com
FULL DISCLOSURE: This is a paid article of Stockhouse Publishing.